Hamlet BioPharma AB publ (FRA:7ZT) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7ZT Hamlet BioPharma AB publ FRA:7ZT
31 GF Score
Price €0.58
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ 5-Year Yield-on-Cost %?

Hamlet BioPharma AB publ FRA:7ZT -2.04% 31 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus rates FRA:7ZT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 149 Biotechnology companies, Hamlet BioPharma AB publ ranks worse than 671140.27% on this metric.

Hamlet BioPharma AB publ's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Hamlet BioPharma AB publ's 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:7ZT's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Hamlet BioPharma AB publ  (FRA:7ZT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Hamlet BioPharma AB publ 5-Year Yield-on-Cost % Related Terms

FRA:7ZT vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Hamlet BioPharma AB publ's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hamlet BioPharma AB publ 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's 5-Year Yield-on-Cost % falls into.


FRA:7ZT
31GF Score
Hamlet BioPharma AB publ FRA:7ZT
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Hamlet BioPharma AB publ is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Hamlet BioPharma AB publ (FRA:7ZT) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hamlet BioPharma AB publ and its competitors. According to the industry distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 149 companies in the Biotechnology industry.
Is Hamlet BioPharma AB publ's 5-Year Yield-on-Cost % too high?
Hamlet BioPharma AB publ's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Hamlet BioPharma AB publ in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Hamlet BioPharma AB publ and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamlet BioPharma AB publ's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (FRA:7ZT) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Hamlet BioPharma AB publ (FRA:7ZT), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges HAMLET B:Sweden
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for FRA:7ZT

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price